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Abstract: Most patients with myelodysplastic syndromes (MDS) are elderly (median age 
range 65 to 70 years); as a consequence, the incidence and prevalence of these diseases are 
rising as the population ages. Physicians are often uncertain about how to identify patients who 
may benefit from specific treatment strategies. The International Prognostic Scoring System 
is a widely used tool to assess the risk of transformation to leukemia and to guide treatment 
decisions, but it fails to take into account many aspects of treating elderly patients, including 
comorbid illnesses, secondary causes of MDS, prior therapy for MDS, and other age-related 
health, functional, cognitive, and social problems that affect the outcome and managing of 
myelodysplastic symptoms. Patients with low-risk disease traditionally have been given only 
best supportive care, but evidence is increasing that treatment with novel non-conventional drugs 
such as lenalidomide or methyltransferase inhibitors may influence the natural history of the 
disease and should be used in conjunction with supportive-care measures. Supportive care of 
these patients could also be improved in order to enhance their quality of life and functional 
performance. Elderly patients commonly have multiple medical problems and use medica-
tions to deal with these. In addition, they are more likely to have more than one health care 
provider. These factors all increase the risk of drug interactions and the consequent treatment of 
toxicities. Manifestations of common toxicities or illnesses may be more subtle in the elderly, 
owing to age-associated functional deficits in multiple organ systems. Particularly important to 
the elderly MDS patient is the age-related decline in normal bone marrow function, including 
the diminished capacity of response to stressors such as infection or myelosuppressive treat-
ments. Through the integration of geriatric and oncological strategies, a personalized approach 
toward this unique population may be applied. As with many diseases in the elderly, reliance 
on family members or friends to maintain the prescribed treatments, including travel to and 
from appointments, may place additional stressors on the patient and his/her support network. 
Careful evaluation and knowledge of functional status, ability to tolerate treatments, effect of 
disease progression, and general overall health conditions can provide the best opportunity to 
support these patients. Immediate assessment of daily living activities may detect deficiencies 
or deficits that often require early interventions.
Keywords: elderly, myelodysplastic syndromes, novel agents, supportive-care, treatment 
strategies
Introduction
Aging is associated with a higher risk of developing malignant diseases in general 
together with increased vulnerability to other age-related health, functional, and 
social problems. The majority of patients with myelodysplastic syndromes (MDS) 
are older than 55 years of age. Aging is an important risk factor for the development Clinical Interventions in Aging 2009:4 414
Ria et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of these diseases. Uncertainty persists about how to identify 
patients who would benefit most from intensive curative 
treatment such as hematopoietic stem cell transplantation 
(HSCT) or from no or low-intensity treatment with growth 
factors, immunomodulating agents, or low-intensity 
chemotherapy for managing disease symptoms. Some 
patients may do best with supportive care alone or may not 
be candidates for any treatment at all. As the proportion of 
older persons in the population increases, it will become 
extremely important to identify which older patients are most 
suitable for different types of therapy.
Epidemiology
MDS comprise a heterogenous group of disorders which are 
the most common hematologic diseases in elderly patients. 
The incidence of MDS from 2001 to 2003 was 3.3 per 
100,000.1 The overall 3-year survival rate was 45%; lower 
for males than for females. In 2004 it was estimated that 
there were about 9,700 patients with MDS in the United 
States, a number that may underestimate its prevalence. MDS 
incidence rates significantly increased with each calendar 
year from 2001 to 2004 and only 4% of patients were reported 
to registries by physicians’ offices.1 Data to support a higher 
incidence of MDS in the United States can be inferred 
from the third National Health and Nutrition Examination 
Survey (NHANES III).2 These show that the prevalence of 
anemia rose sharply in adults over 50, exceeding 20% for 
those aged 85 and older. Overall, 11% of men and 10.2% of 
women 65-years or older were anemic. One-third of those 
with anemia presented evidence of nutrient deficiency, 
another third presented anemia of chronic disease and/or 
renal insufficiency, and those remaining were diagnosed 
with unexplained anemia. MDS is likely to be a more precise 
diagnosis for many patients classified as having unexplained 
anemia. Among them, 17.2% (5.8% of the total population 
with anemia) had macrocytosis accompanied by neutropenia 
or thrombocytopenia, suggesting that the population of 
patients with MDS may be higher than estimated.2
Clinical features
MDS constitutes a heterogenous group of hematopoietic stem 
cell disorders (Table 1) which are characterized by various 
degrees of anemia, leukopenia, and thrombocytopenia, 
as well as an increased risk for developing acute myeloid 
leukemia (AML). Hematopoietic progenitors in MDS show 
a decreased capacity for differentiation and an increased 
tendency for apoptosis leading to ineffective hematopoiesis. 
Cytogenetic and molecular data provide evidence for a 
clonal hematopoietic stem cell disorder in the majority of 
cases. Cause, unless associated with prior chemotherapy, 
radiation, or toxic exposure, eludes discovery.4,5 In most cases, 
ineffective hematopoiesis leads to compensatory bone marrow 
hyperplasia. Over time many patients develop an increase in 
bone marrow blasts, about 30% developing AML.
The clinical variation MDS presents ranges from 
indolent to life-threatening. Up to 10% of patients with MDS 
experience serious bleeding, including hematuria and gastro-
intestinal, retinal, and central nervous system hemorrhage. 
They may also develop Sweet’s syndrome, splenomegaly 
(in 10% to 20% of patients), and hepatomegaly (5% to 26%). 
In chronic myelomonocytic leukemia, however, the incidence 
of splenomegaly and hepatomegaly increases to 30% to 50%, 
and the spleen may be massively enlarged. In general, lymph 
node enlargement is seen in 5% to 15% of these cases.
To assist in decision making regarding treatment, a risk-
adapted approach has been adopted and is widely accepted. 
The International Prognostic Scoring System (IPSS) (Table 2) 
is based on karyotype, number of significantly cytopenias, 
and percentage of bone marrow myeloblasts. It provides a tool 
to measure the probability of survival and risk for progression 
towards AML in untreated patients with MDS. The IPSS 
is widely accepted as a valid tool to measure prognosis, and 
the cytogenetic risk stratification system of the IPSS has 
proven to be an independent prognostic marker in studies 
of high-risk MDS and AML following MDS.6
According to recommendations of an International 
Working Group, the major goal of therapy for patients with 
lower-risk disease (low-risk and intermediate-1 categories, 
as defined by the IPSS) is hematologic improvement and 
management of symptoms with the aim of improving the 
quality of life.7
For higher-risk patients (intermediate-2 and high-risk 
categories), the focus turns to modifying the natural history 
of the disease and extending survival.8 These prognostically 
distinct therapeutic achievements have only recently been 
identified as new data demonstrate certain therapies for 
lower-risk may modify the overall course of the disease 
improving survival and quality of life. Supportive care 
for MDS includes red blood cell transfusion, platelet 
transfusion, iron chelation therapy to reduce transfusional 
hemosiderosis, and hematologic growth factors (when 
appropriate) to raise neutrophil and hemoglobin levels. 
New therapies for this disease, including low-intensity 
chemotherapies and immunomodulators, may enhance 
hematologic improvement, decrease the rate of leukemic 
transformation, and improve overall survival; they are now Clinical Interventions in Aging 2009:4 415
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being used to treat low-risk disease.9 For patients with 
high-risk disease, high-intensity treatments such as leukemia-
type induction therapy and HSCT are used and are briefly 
taken into consideration in this review.
As more low-risk patients are being treated with low-
intensity chemotherapy and immunomodulating agents, with 
the aim of altering the trajectory of the disease, the IPSS 
classification system, which emphasizes pretreatment prognos-
tic factors, becomes more difficult to apply and is becoming an 
outdated measuring tool. Several investigators have proposed 
alternative prognostic tools including serial application and 
incorporating World Health Organization criteria into the IPSS 
(becoming WPSS),10 adding serum lactate dehydrogenase as 
a prognostic variable,11 and more risk stratification of low-risk 
disease.12 New prognostic scoring methods have been proposed 
by the M.D. Anderson group, taking into account prior low-
intensity treatment, secondary disease, performance status, and 
transfusion requirements, in addition to measurements used in 
Table 1 WHO classification and criteria for the myelodysplastic syndromes3
Disorder Peripheral blood Bone marrow
Refractory anemia (RA) Anemia erythroid dysplasia only
No or rare blasts 5% blasts
15% ringed sideroblasts
Refractory anemia with ringed 
sideroblasts (RARS)
Anemia erythroid dysplasia only
No blasts 5% blasts
15% ringed sideroblasts
Refractory cytopenia with multilineage 
dysplasia (RCMD)
Bi- or pan-cytopenia Dysplasia in 10% of cells in 2 or more 
myeloid cell lines
No or rare blasts No Auer rods
No Auer rods 5% blasts
Monocytes 1,000/µL 15% ringed sideroblasts
Refractory cytopenia with multilineage 
dysplasia and ringed sideroblasts 
(RCMD-RS)
Bi- or pan-cytopenia Dysplasia in 10% of cells in 2 or more 
myeloid cell lines
No or rare blasts No Auer rods
No Auer rods 5% blasts
Monocytes 1,000/µL 15% ringed sideroblasts
Refractory anemia with excess blasts-1 
(RAeB-1)
Cytopenias Unilineage or multilineage dysplasia
5% blasts 5% to 9% blasts
No Auer rods No Auer rods
Monocytes 1,000/µL
Refractory anemia with excess blasts-2 
(RAeB-2)
Cytopenias Unilineage or multilineage dysplasia
5% to 19% blasts 10% to 19% blasts
Auer rods ± Auer rods ±
Monocytes 1,000/µL
MDS-unclassified (MDS-U) Cytopenias Unilineage dysplasia in granulocytes  
or megakaryocytes
No or rare blasts No Auer rods
No Auer rods 5% blasts
MDS with del (5q) “5q-syndrome” Anemia Normal to increased megakaryocytes with 
hypolobulated nuclei
5% blasts No Auer rods
  Platelets usually normal  
or increased
5% blasts Isolated del (5q)Clinical Interventions in Aging 2009:4 416
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the IPSS.13 In addition to the biologic and clinical properties 
of MDS, however, the treatment becomes significantly com-
plicated due to the older population, their co-morbid illnesses, 
difficulties of access to care, social situations, cognitive status, 
and the large variation in functional status. Given these fac-
tors, decision making about treatment for elderly patients is 
extremely complex and geriatric factors need to be incorpo-
rated into prognostic scoring for MDS.
Quality of life in MDS patients
When treatments are unsatisfactory there are two main areas to 
be taken into consideration. In the first, therapeutic approaches 
which alleviate symptoms but do not affect the underlying 
disease or prognosis are taken into account. In the second a 
therapeutic benefit in terms of prognosis is achieved, but a 
considerable price of toxicity or hospitalization is expected.
Quality of life could be defined as a multidimensional 
construct based on somatic, emotional, mental, social and 
behavioral components of well-being and function from the 
point of view of the patient and/or external observers.14
MDS seriously affect the quality of life of patients. 
Although there have been considerable improvements in 
available therapies, once diagnosed, the disease will dominate 
much of the remaining time of the patient and potentially 
be the cause of death unless competing co-morbidities are 
present or allogeneic stem cell transplant is possible.
Suffering from MDS causes a substantial and persistent 
functional decrement in a variety of areas, including the 
above mentioned, partially due to fatigue (81% of patients). 
A negative impact on quality of life results from the time 
and effort required to cope with the disease such as frequent 
visits to doctors, administering therapy, and managing side 
effects. Patients have often viewed the emotional impact of 
MDS (shock, anger, depression, and anxiety) as being more 
problematic than the physical consequences.
Among the cytopenias which define MDS, anemia has 
the most prominent influence. Low hemoglobin values 
are a key determinant of fatigue, a key determinant of 
quality of life. Although frequent and unusual infections 
may contribute to physical complaints, this is rarely a 
major issue in the early stages of the disease. MDS related 
thrombocytopenic bleeding is usually confined to later 
stages and progression to leukemia. Moreover, there may 
be other physiological (rather than psychological) reasons. 
For other neoplastic diseases, it has been shown that altered 
cytokine levels contribute to alterations of physical and 
psychological well-being,15 which may be the case in patients 
with MDS/leukemia;16,17 in polytransfused patients the 
evolving secondary hemochromatosis may also contribute 
to the number of symptoms MDS patients have to bear. 
Manifestations may range from increased fatigue to overt 
heart failure, but due to the underlying disease and the high 
rate of co-morbidity in the elderly patients, it remains difficult 
to ascertain the contribution of the various etiologies to the 
respective symptom.18
Management
Observation (‘watch and wait’)
Observation with periodic blood counts, also called 
‘watch and wait’, is generally recommended for a patient 
Table 2 International Prognostic Scoring System (IPSS)7
Factor Value IPSS score Notes
Blasts 5% or less 0
5% to 10% 0.5
11% to 20% 1.5
21% to 30% 2.0
Cytogenetics = Good 0 Normal; -Y only; 5q- only; or 20q- only
= Intermediate 0.5 Abnormalities other than good or poor
= Poor 1.0 Complex; 3 or more abnormalities or abnormal chromosome 7
Cytopenias  0/1 
2/3
0 
0.5
Hemoglobin 10 g/dL; absolute neutrophil count (ANC) 1,500/µL; 
platelet count 100,000/µL; each count as a value of 1.
Notes: The numeric scores for the blast %, the cytogenetic changes and the cytopenias are combined to give the total numeric score.   The scores equal a risk category:
  •  Low.
  •  Intermediate-1.
  •  Intermediate-2.
  •  High.
The risk categories are sometimes combined as
  •  Low and intermediate-1 = low-risk MDS.
  •  Intermediate-2 and high = high-risk MDS.Clinical Interventions in Aging 2009:4 417
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with a low or intermediate-1 risk hemoglobin level 
greater than 10 g/dL and platelet counts of 50,000/µL to 
100,000/µL, without need for transfusion. These patients 
may be able to maintain their usual activity levels without 
therapy.
Some patients have little change in status for years. 
However, regular check-ups are important, in that there 
is a risk of progression to more severe forms of MDS or 
AML. It is therefore important for a patient to have an MDS 
specialist do periodic health status evaluations and monitor 
blood cell counts on a regular basis.
Anemia in MDS: its importance 
in the geriatric patient
Recent, extended, observational epidemiologic studies have 
consistently documented that anemia, even if not severe, is 
strongly and independently associated with major adverse 
functional outcomes in community-dwelling of older 
adults, including the decline in physical and cognitive 
function, frailty, and disability.19 Evidence has also shown 
that anemia interacts with common co-morbidities to 
synergistically increase the risk of outcomes such as frailty 
and mortality.20,21 Anemia is most often defined by World 
Health Organization criteria (hemoglobin 12 g/dL for 
women and 13 g/dL for men), but these criteria do not 
consider the debilitating effects of mild anemia on the 
elderly population. It is not clear if a lower hemoglobin 
concentration for post-menopausal women is valid or 
whether the same threshold should be used for both men and 
women.22 Racial differences may be important in assessing 
optimal hemoglobin concentration, and this research will 
be important in determining the best supportive care for 
MDS patients. More research involving the community-
dwelling of the elderly population is needed to determine 
optimal hemoglobin levels for elderly patients and the effect 
of treatment for mild anemia on outcome. Patients with 
MDS often have severe anemia, which contributes to their 
overall prognosis, exacerbating the symptoms of co-morbid 
illnesses and influencing functional, cognitive, and social 
deterioration in their lives. Using current prognostic scales, 
anemia in all MDS patients should be aggressively treated to 
improve functional and cognitive status in order to improve 
quality of life.
Anemia in MDS: supportive care strategies
Red blood cell transfusion
Initiation of transfusion therapy should be based on clinical 
evaluation of anemia-related symptoms and co-morbid 
illness rather than on a defined hemoglobin level, especially 
because optimal hemoglobin levels have not been defined for 
the elderly population.23 In clinical practice, pre-transfusion 
hemoglobin levels in MDS are generally maintained 
between 8 and 10 g/dL, but all quality of life studies show 
significantly greater fatigue and dyspnea in MDS patients 
rather than in healthy controls, and it is not known whether 
a more liberal transfusion strategy can improve quality of 
life or outcome.24
Iron chelation therapy
Chronically transfused MDS patients invariably develop iron 
overload, which can lead to organ damage and dysfunction. 
Evidence of the direct role of iron in organ damage in MDS 
is still limited, and clinical information is usually inferred 
from other transfusion-dependent anemias, especially 
thalassemia. The time from onset of transfusion to the 
development of organ damage caused by iron overload is 
well defined in the thalassemia cohort, but this time may not 
apply to the elderly MDS patient.
There is evidence from a small-scale study that iron 
chelation has efficacy in elderly MDS patients. The 
administration of oral deferasirox (Exjade®: 20 to 40 mg/kg 
per day) in transfusion-dependent MDS patients induces 
a significant decrement of the mean serum ferritin after 
12 months of therapy. The labile plasma iron concentration 
normalized in all patients within 3 months and was sustained 
throughout the first year of treatment. Reversible elevation in 
serum creatinine occurred in 25% of the patients.25
Moreover, in patients who received standard chelation 
therapy with subcutaneous deferoxamine (Desferal®), 
deferiprone (Ferriprox®), or deferasirox, or low-dose 
chelation with subcutaneous bolus deferoxamine or 
intravenous deferoxamine after transfusions the median 
overall survival from the time of diagnosis was better 
than in nonchelated patients (115 months vs 51 months; 
P  0.0001). After stratification by prognostic variables 
including IPSS category, age, sex, and transfusion require-
ments, the survival difference favoring the chelated group 
remained significant.26
Although these studies suggest that iron chelation 
treatment is beneficial, there are still uncertainties. More 
research needs to be done to determine the best time to initiate 
treatment. Oral iron chelation therapy is expensive and is 
linked to renal insufficiency. This therapy may be difficult for 
older patients to tolerate. More intense studies are needed to 
determine the survival benefit, cost feasibility, and the right 
moment to begin the therapy.Clinical Interventions in Aging 2009:4 418
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erythropoiesis-stimulating agents
Recombinant human erythropoietins in doses ranging from 
30,000 to 60,000 units/week can be effective in MDS. 
A meta-analysis of more than 200 patients from 17 studies 
showed that treatment rHuEpo as monotherapy induced 
erythroid responses in about 15% of patients with MDS.27 
Two phase 3, randomized controlled trials evaluated the 
use of rHuEpo vs placebo. The larger of these studies 
enrolled 87 patients with hemoglobin less than 9 g/dL and 
bone marrow blasts less than 10%. The response rate was 
37%. Patients with refractory anemia (RA) in the French-
American-British (FAB) classification system had a higher 
probability of response, but in patients with refractory 
anemia with ringed sideroblasts (RAS) and refractory 
anemia with excess blasts (RAEB), the responses were not 
significantly different from those with placebo. A higher 
response rate was observed in patients without prior trans-
fusions and in those with low pretreatment erythropoietin 
levels (150 to 200 U/L).28
The most widely adopted response criteria are those 
of the Nordic and French MDS Groups, which define a 
complete erythroid response as an increase in hemoglobin 
level to at least 11.5 g/dL without red blood cell transfusions; 
a partial erythroid response is defined as no transfusion 
requirement or an increased hemoglobin level of more than 
1.5 g/dL for patients with non-transfused anemia.29 There is 
no consistent information on the length of treatment before 
assessing response. Most often, responses occur between 
12 and 16 weeks, but additional responses may be observed 
if treatment is continued as long as 6 months. In a phase II 
trial in 281 MDS patients conducted for The Greek MDS 
Study Group Terpos et al prolonged administration of 
rHuEpo produces high and long-lasting erythroid response 
rete in MDS patients with low blast counts, particularly in 
those with pretreatment serum Epo levels of  150 U/L and 
good cytogenetic prognosis.30 They evaluated the response to 
treatment after 12 and 26 weeks of therapy with a significant 
increase in response rate observed at week 26 in RA, RARS 
and RAEB-I patients, as the response probability increased 
with treatment duration.
Treatment with darbepoetin alpha, a highly glycosylated 
erythropoiesis-stimulating agent with a longer half-life than 
epoetin alpha, has produced comparable response rates at 
dosing intervals ranging from 1 to 3 weeks.31 Treatment with 
erythropoiesis-stimulating agents may improve quality of life 
in patients and reduce the need for transfusion support.
Golshayan et al conducted a pooled analysis in 1,869 
MDS patients with low-risk disease according to treatment 
with erythropoiesis-stimulating agents.32 A survival benefit 
was observed in patients who received an erythropoiesis-
stimulating agent, and this difference was maintained even 
after outcomes were corrected for FAB type, baseline 
transfusion requirements, IPSS category, prior treatments, 
and interval from diagnosis.
Treatment with erythropoiesis-stimulating agents has 
come under scrutiny during the past year. The US Food 
and Drug Administration (FDA) has strengthened safety 
warnings based on concerns in solid-tumor trials showing 
increased mortality from the underlying disease and increased 
risk for thromboembolism, particularly in studies targeting 
higher hemoglobin levels (12 mg/dL). This information 
prompted the Centers for Medicare and Medicaid Services 
to limit coverage for erythropoiesis-stimulating agents for the 
treatment of chemotherapy-induced anemia, but they have 
elected to exclude MDS from the national coverage decision. 
Available data involving the use of erythropoiesis-stimulating 
agents in MDS show that these agents improve symptoms 
and decrement transfusion requirements. The extent to which 
they improve functional and cognitive symptoms associated 
with anemia in MDS patients has not been documented and 
should be a focus for further research.
Treatment of other cytopenias
Neutropenia and secondary infections
Severe neutropenia in low-risk MDS usually occurs in the 
setting of pancytopenia, but can be an isolated clinical 
problem. There is no indication for prophylactic use of 
granulocyte colony-stimulating factor (G-CSF) in MDS, 
but this drug can be an option for individual patients with 
severe neutropenia and recurrent infections. Prophylactic 
antibiotics are also used in MDS patients with neutropenia. 
Many studies document the efficacy of using prophylactic 
fluoroquinolone antibiotics in neutropenic patients to prevent 
febrile neutropenia and bacteremia and to reduce days of 
hospitalization.33
Prophylaxis in elderly MDS patients has drawbacks 
that need to be considered. Numerous reports have linked 
the use of prophylactic antibiotics to the emergence 
of resistant organisms, an important consideration for 
patients who may be expected to have neutropenia for a 
long period.
Where there are high levels of resistance to fluoro-
quinolones (such as in some nursing homes and assisted 
living communities), the resistance pattern should prompt a 
reconsideration of prophylactic strategies. It is also important 
to ensure that prophylactic antibiotics and antifungals do Clinical Interventions in Aging 2009:4 419
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not interact with other medications in patients using large 
numbers of prescription drugs to treat co-morbid illnesses. 
These patients may also need assistance to administer 
medications.
Thrombocytopenia and bleeding-related disorders
Severe thrombocytopenia with chronic bleeding is a serious 
clinical problem in MDS and is associated with shortened 
survival and impaired quality of life. Platelet transfusions 
may provide short-term relief for bleeding tendencies but 
cannot prevent long-term symptoms.
Megakaryocytopoiesis has been difficult to stimulate 
in vivo. The FDA recently approved a drug for treatment of 
immune thrombocytopenia, namely AMG 531. This drug is 
currently in clinical trial for MDS patients and may prove 
beneficial to elderly patients with this disease.34
Treatment strategies
Curative therapy for MDS
High-dose chemotherapy followed by HSCT is presently the 
only treatment with curative potential in MDS. Historically, 
experience has demonstrated that about 40% of patients 
may be cured with hematopoietic stem cell transplant, but 
advanced age, co-morbid medical problems, procedure 
morbidity and mortality, and lack of donor availability limit 
the procedure to a small, select minority.35,36 In particular 
subjects older than 50 years, age and blast percentage 
at HSCT are the most important factors for outcome of 
trasplanted patients37,38 and for the choice of myeloablative or 
non-myeloablative conditioning regimen.39 Moreover, due to 
increasing age that non-myeloablative transplant will be done, 
the availability of transplant for elderly MDS is expanding.
Decision models are available to assist in determining 
which MDS patients should undergo hematopoietic stem cell 
transplant and whether they are fit.40,41 However, these models 
do not consider functional, cognitive, and social situations that 
affect elderly patients’ long-term ability to lead independent, 
functional lives and to maintain an acceptable quality of life 
after transplantation. Optimal models for selection of older 
patients for aggressive therapy with hematopoietic stem cell 
transplant have not been developed.
Non-curative therapy for MDS
Growth factors can be an effective tool in treating low risk 
MDS, but the vast majority of MDS patients with transfu-
sion requirements of two units of red blood cells per month 
or elevated erythropoietin levels are unlikely to respond to 
this treatment.
In the past decades many attempts to improve survival of 
MDS patients have been made, but the results have always 
been disappointing.
Hormonal therapy
Hormone therapy has been used to improve hematologic 
parameters in MDS patients. Androgens have been suggested 
to improve anemia, leukopenia, and thrombocytopenia, but 
results from trials have been inconsistent.42
Differentiating agents
Low-dose cytarabine has been reported to possess the ability 
to induce differentiation of the leukemic cell line in vitro, 
and trials have been done on patients with MDS.43–45 Retinoid 
differentiating activity has been established in studies of 
promyelocytic leukemia, but trials in MDS, however, have 
failed to show any impact.46 Retinoic acid may also accelerate 
the transformation of MDS to AML,47 but again studies on the 
treatment of MDS patients with other differentiating agents 
such as vitamin D3, interferon alpha, and interferon gamma 
are quite disappointing.48
Chemotherapy
Chemotherapy trials for MDS using standard antileukemic 
drugs in different dosages and combinations using daunoru-
bicin, cytosine arabinoside (ara-C), 6-thioguanine indicate 
that CRs have occurred (8% to 56%) but at the cost of a high 
incidence of deaths from toxicity (24% to 64%).48
While the majority of MDS and MDS/AML patients 
have hypercellular bone marrow, 10% to 15% have marrow 
hypocellularity. Hypocellular MDS patients may have 
longer survival and may progress to AML less frequently. 
These hypocellular MDS/AML patients represent the best 
candidates to observation or growth factors administration 
also because with chemotherapy they may have more 
complications and less chance of achieving remission.49
New strategies
There is evidence that treating patients with immunomodu-
latory therapy or low-intensity therapy may alter the long-
term course of the disease and improve quality of life and 
survival.
Lenalidomide (Revlimid®)
The pathogenesis of MDS involves a complex biologic 
interaction that fosters increased angiogenesis, overproduc-
tion of proinflammatory cytokines, accelerated apoptosis 
of hematopoietic progenitors, and autocrine stimulation by 
vascular endothelial growth factor. Immunomodulatory drugs Clinical Interventions in Aging 2009:4 420
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such as lenalidomide can alter the bone marrow environment 
and can potentially interfere with this complex series of 
events. Lenalidomide is a second-generation immunomodu-
latory drug; it is more potent and less neurotoxic than its 
predecessor, thalidomide. The MDS-003 clinical trial was the 
pivotal study evaluating the efficacy of lenalidomide in lower-
risk, transfusion-dependent patients with a chromosome 5q31 
deletion, with or without other cytogenetic abnormalities. 
The clinical trial showed that 76% of patients who received 
lenalidomide had a 50% or greater reduction in transfusion 
requirements; 67% became transfusion-independent, with a 
rise in hemoglobin of 1 g/dL or more. The median duration 
of transfusion independence was 2 years. The most common 
adverse events were neutropenia and thrombocytopenia.50
Lenalidomide has also been evaluated in low-risk 
patients without del(5q). In a large, multicenter trial, 56 of 
214 patients achieved red blood cell transfusion indepen-
dence with a rise in hemoglobin of 1 g/dL or more, and an 
additional 17% had a 50% or greater reduction in transfusion 
requirements.51
An advantage of using this agent to treat elderly patients 
with MDS is that it is an oral agent that can be easily managed 
in the outpatient setting. Patients need careful monitoring of 
blood counts and supportive transfusion, but they do not need 
to come to the physician’s office to receive infusional therapy 
and do not need any inpatient monitoring.
Methyltransferase inhibitors
Hypermethylation of cytoside residues on DNA and 
consequent chromatin condensation are key features of the 
malignant phenotype that lead to epigenetic silencing of 
genes involved in the control of normal cell growth and differ-
entiation. Methyltransferase inhibitors are a class of medica-
tions that deplete nuclear DNA methyltransferase, the enzyme 
responsible for methylation of the DNA; as a consequence, 
they promote demethylation in newly synthesized DNA.
Two Methyltransferase inhibitors are approved for treat-
ment of MDS: azacitidine and decitabine. Both are cytosine 
analogues that are distinguished by their sugar moieties, 
which may account for different activity.
Azacitidine (vidaza®)
Encouraging results from the phase 2 trials of azacitidine, 
initiated by the Cancer and Leukemia Group B, led to a phase 
3 study that compared treatment with azacitidine vs best 
supportive care in patients with MDS (any FAB subtype). 
Patients in the best supportive care arm were allowed to cross 
over to azacitidine if they experienced progression of disease. 
Responses to azacitidine were observed in all FAB subtypes, 
with a complete response (CR) plus partial response (PR) 
in 22% and hematologic improvement in 37% of patients. 
Median time to AML transformation was 13 months in the 
best supportive care group compared with 21 months in the 
azacitidine arm (P = 0.007).52
A phase 3, randomized, multicenter trial (AZA-001) 
compared azacitidine treatment using the FDA-approved 
dosing schedule with conventional care regimens in 
previously untreated patients having IPSS intermediate-2 
or high-risk RAEB, RAEB in transformation (RAEB-t), 
or chronic myelomonocytic leukemia.53 Before randomiza-
tion, patients selected three Conventional Care Regimens 
strategies: a) best supportive care; b) low-dose cytarabine; 
c) standard AML-type induction therapy with consolidation 
chemotherapy. Azacitidine was continued until evidence of 
disease progression or treatment intolerance. In this study, 
358 patients were randomized to either azacitidine (n = 179) 
or conventional care regimens (n = 179) with a primary 
endpoint of overall survival. Azacitidine was administered 
for a median of nine cycles. There was a significantly 
improvement in overall survival (median, 24.4 months vs 
15 months with conventional care regimens; P = 0.0001, 
hazard ratio = 0.058) across all IPSS categories. Survival 
after 2 years was nearly doubled with azacitidine (51% vs 
26%, P  0.0001). Azacitidine treatment was superior to all 
conventional care regimens, with corresponding extension 
in median overall survival of 12.9 months vs best supportive 
care, 9.1 months vs low-dose cytarabine, and 8.7 months 
vs standard induction therapy. Response rates also favored 
azacitidine; more patients achieved major and minor 
responses with azacitidine than with any conventional care 
regimens.53 The improvement in overall survival despite 
a modest CR rate of 17% indicates that azacitidine acts 
in a distinctive way that differs from that of conventional 
cytotoxic drugs and leads to reduced leukemic potential.
Decitabine (Dacogen®)
A phase 3 trial of another MTI, decitabine, led to FDA 
approval for this drug for the treatment of AML and MDS 
(intermediate-1, intermediate-2, and high-risk IPSS). 
Patients were randomized to receive best supportive care 
or decitabine (15 mg/m2), given intravenously over 3 hours 
every 8 hours for 3 days and repeated every 6 weeks for 
up to 6 cycles. Patients who received best supportive care 
could cross over and receive decitabine after transformation 
to AML. End points for the trial were CR and PR, time into 
AML transformation, or death. The overall response rate was Clinical Interventions in Aging 2009:4 421
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30% (CR 9%, PR 8%, hematologic improvement 13%), but 
there was no difference between treatment arms in the median 
time to death or transformation into AML. Overall mortality 
in patients treated with decitabine was 10%; neutropenia 
developed in 87% of these patients and grade 3 or 4 throm-
bocytopenia occurred in 85%.54
Apparently the two phase III trials on methyltransferase 
inhibitors have different results, but they cannot be correctly 
compared because of the different design of the 2 studies. 
In fact, the control harm are quite different: in the study of 
azacitidine the control harm is composed by best supportive 
care, low-dose cytarabine, or intensive chemotherapy as 
selected by investigators before randomization, while in the 
decitabine study the control harm is only best supportive care. 
However, the comparison of results obtained in decitabine 
trial with the group received only best supportive care in the 
control harm of azacitidine study gave similar results.
Antithymocyte globulin  
(ATG;   Thymoglobuline®;   Atgam®)
Some MDS patients have disease characterized by lympho-
cytes that destroy precursors of normal red cells, neutrophils 
and platelets. ATG is an immune globulin that is obtained 
from rabbits or horses and is given intravenously, destroys 
lymphocytes and improves blood counts in some MDS 
patients. A single course of ATG restored hemopoiesis in 
some patients with MDS, particularly in patients with RA 
and RAEB with a median response duration of 10 months 
and is well tolerated with only immediate fever and chills as 
common side effects after ATG administration.55
It is possible to identify patients with better or worse 
chances of responding to ATG or other immunosuppressive 
agents such as cyclosporine.56–58 These are those with low 
or intermediate-1 IPSS risk or that express HLA-DR15 
antigen.
Current clinical trials in MDS
The goal of clinical trials for MDS is to improve treatment and 
quality of life and to increase survival. Patients’ participation 
in clinical trials is needed to improve standard therapies, so 
that all MDS patients can one day be cured of this disease. 
Some clinical trials are for all MDS-risk types; others are for 
either lower-risk or higher-risk MDS. Patients should speak 
to their doctors about the benefits of treatment in a specific 
clinical trial. Eligibility for a trial may depend on the patient’s 
age, risk type and previous treatment for MDS.
There are several clinical trials to study treatment with 
combinations of FDA-approved drugs, such as azacitidine 
or decitabine, and AML-type chemotherapy. The idea of 
combining agents is that, since each works in different ways 
to kill cancer cells, using them together may kill more MDS 
cells or be as effective as standard MDS therapies, but with 
less-toxic side effects.
Trials are currently estimating: i) the effectiveness of 
arsenic trioxide (Trisenox®) in combination with azaciti-
dine or with tipifarnib (Zarnestra®), a farnesyl transferase 
inhibitor, and gemtuzumab ozogamicin (Mylotarg®); ii) if the 
duration of response improves with azacitidine maintenance 
for patients who achieve a complete or partial remission after 
intensive chemotherapy; iii) the effectiveness of clofarabine 
(Clolar®) in combination with AML-type chemotherapy; 
iv) the effect of lonafarnib (Sarasar®) and tipifarnib 
(Zarnestra®) on transfusion independence for patients 
who receive between 1 to 8 platelet transfusions every 
4 weeks; v) the effectiveness of valproic acid (Depakene®) 
in combination with decitabine; vi) the effectiveness of 
vorinostat (Zolinza®) in combination with azacitidine.
Conclusions
There are many complex variables in the treatment of elderly 
patients with MDS. As the elderly population increases 
worldwide, the proportion of elderly patients with MDS 
will also rise and the costs of treating this disease will 
be substantial. Evidence-based strategies are needed to 
determine which patients are best suited to low-intensity 
treatment, high-intensity treatment with hematopoietic stem 
cell transplant, best supportive care, or no treatment. These 
stratification methods should consider biologic factors of 
the disease, co-morbid illness, depression, functional status, 
cognitive status, and social situation.
To make a choice of management in older MDS patients the 
first step must be an integrating geriatric and oncology nursing 
strategies allows an individualized approach toward this unique 
population. All the factors influence the potential inability of 
the older patient to tolerate certain intensive forms of therapy 
must be considered and particularly multiple medical problems 
affect older population and use medications to manage them. 
Particularly important in the elderly MDS patient is the evalua-
tion of the age-related decline in normal bone marrow function, 
including diminished capacity for response to stressors such 
as infection or myelosuppressive treatments. Further observa-
tion may be useful to determine if the patient has an indolent 
or progressive course, to evaluate if the MDS is presented as 
isolated but persistent mild anemia or as a more progressive 
and aggressive anemia state that accumulates excess blasts 
in the marrow and leads to fatal AML. So, patients may be Clinical Interventions in Aging 2009:4 422
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categorized by age, co-morbidities and by stable vs unstable 
disease before suggesting specific treatment approaches. 
To improve access to treatment, emphasis must be placed 
on oral therapies, which can be easily administered in the 
outpatient setting with growth-factor support to minimize 
transfusion. Intensive efforts are needed to find strategies that 
keep elderly patients functional and in their homes during treat-
ment, minimizing time in the physician’s office and hospital.
In conclusion, careful evaluation of functional status, 
ability to tolerate treatments, effect of disease progression, 
and general overall health can provide the best opportunity 
for support of older patients, considering that palliation 
and supportive care represent important components to 
maximizing quality of life.
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